2-Cyclopropylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Cyclopropylalanine
• 英文别名: (2R)-2-amino-2-cyclopropylpropanoic acid
• 化学式: C₆H₁₁NO₂
• 分子量: 129.16
• InChiKey: VRFYYCFVOBCXDL-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Janssen Pharmaceutica, NV

  公开号：US20150166529A1

  公开（公告）日：2015-06-18

  The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , m, n, and are defined herein.

  本发明涉及咪唑啉-5-酮衍生物，含有它们的药物组合物，以及它们作为FASN抑制剂的用途，例如用于治疗癌症、肥胖相关疾病和肝脏相关疾病。此类化合物由以下式子表示： 其中R1、R2、R3、R4、R5、m、n和在此处定义。
• Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
  申请人：Roche Diagnostics GmbH

  公开号：EP0967201A1

  公开（公告）日：1999-12-29

  The invention concerns the use of sulfonamids of formula I as matrix metalloprotease (MMP) inhibitors wherein R1, X, R12, R13, R14 and R15 have the above stated meanings as well as their racemates, diastereomers, pharmacologically acceptable salts or prodrugs thereof, to produce pharmaceutical agents for the treatment of diseases where MMP activity is involved.

  本发明涉及使用I式磺酰胺作为基质金属蛋白酶（MMP）抑制剂，其中R1、X、R12、R13、R14和R15具有上述所述的含义，以及它们的外消旋体、对映异构体、药理学上可接受的盐或前药，以制备用于治疗涉及MMP活性的疾病的药物制剂。
• DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS
  申请人：Simpson Iain

  公开号：US20090312336A1

  公开（公告）日：2009-12-17

  Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.

  本文介绍了化学式(I)的化合物，或其药理学上可接受的酸盐，并描述了它们在抑制PLK活性方面的用途。
• Peptide containing an arginine mimetic for the treatment of osteoporosis, their production, and drugs containing these compounds
  申请人：Roche Diagnostics GmbH

  公开号：EP0902036A1

  公开（公告）日：1999-03-17

  The present invention is directed to compounds of general formula (I) wherein R1, R2, R3 and X may be the same or different, and wherein R1, R2 represent hydrogen, an amino acid, peptidyl, alkyl or aryl residue; R3 represents hydroxy, lower alkoxy, or an -NR31R32 residue where R31, R32 and represent idependently hydrogen, an aminoacid, peptidyl, alkyl or aryl residue; X represents an amino acid or a peptide; R4 represents hydrogen, hydroxy, amino or C1-C4-alkyl; m represents a number between 0 and 5; R5 represents an optionally substituted saturated or unsaturated mono- or bicyclic moiety which may contain one or more heteroatoms, a C1 -C11 alkyl group which may have substitutions or intermittent heteroatoms. their tautomers, optical isomers, pharmaceutically acceptable salts and prodrugsas well as their production and their use as medicaments.

  本发明涉及通式 (I) 的化合物 其中 R1、R2、R3 和 X 可以相同或不同，其中 R1、R2 代表氢、氨基酸、肽基、烷基或芳基残基； R3 代表羟基、低级烷氧基或 -NR31R32 残基 其中 R31、R32 和分别代表氢、氨基酸、肽基、烷基或芳基残基； X 代表氨基酸或肽； R4 代表氢、羟基、氨基或 C1-C4- 烷基； m 代表 0 至 5 之间的数字； R5 代表任选取代的饱和或不饱和单环或双环分子，可含有一个或多个杂原子，C1-C11 烷基，可含有取代或间歇杂原子。 它们的同分异构体、光学异构体、药学上可接受的盐和原药，以及它们的生产和作为药物的用途。
• Malonic acid based matrix metalloproteinase inhibitors
  申请人：Roche Diagnostics GmbH

  公开号：EP0911319A1

  公开（公告）日：1999-04-28

  The invention concerns compounds which are represented by the general formula I, wherin the meaning of the substitutes is given in the claims, their process of production and their use as MMP inhibitors.

  本发明涉及通式 I 所表示的化合物（权利要求书中给出了代用品的含义）、其生产工艺以及作为 MMP 抑制剂的用途。